Sanofi Shares Drop to €71.73: A New Six-Year Low
Sanofi shares fell by 1.04% to €72.46 in mid-morning trading, after hitting €71.73 during the session, marking a new six-year low. This level surpasses the previous low recorded during the Covid-19 crash in 2020, at €72.74. The CAC 40 was down 0.62% at the same time, at 8,006.25 points.
A New Historic Post-Covid Low Reached During the Session
The laboratory continues to set new low records. The stock marked €71.73 as the lowest of the day, below the previous low of €72.74 from spring 2020. The decline reaches 6.88% over a week and 22.02% over a year. The drop follows the previous low on May 8 at €72.78 and the downgrade by Morgan Stanley at the beginning of May, which triggered a 2% decline. In terms of valuation, the stock is trading at about 8.5 times the expected earnings for the current fiscal year, compared to 18.9 times for the average of the Health Care sector according to the consensus of 19 analysts (updated as of May 6, 2026). The expected EPS growth from one year to the next is estimated at 5.8%.
Technical Indicators in Oversold Territory, Support Tested
The price touches the lower boundary of the Bollinger Bands at €72.40, signaling an oversold configuration. The RSI at 30 confirms the selling exhaustion observed over the week. The stock remains well below its 200-day moving average (€82.08), with a gap of 11.72%. The technical support at €73.10 was breached during the session, paving the way to the psychological level of €72. The company continues to make progress on its clinical files: Dupixent had crossed the €4 billion sales mark in the first quarter of 2026, announced on April 23, and tolebrutinib received a favorable opinion from the European CHMP on April 27. The next key event for the market: the publication of the second quarter 2026 results, expected on July 30.
